Safety and Immunogenicity of the Candidate Vaccine MVA-SARS-2-S and a Booster Vaccination With a Licensed Vaccine Against COVID-19

Phase 1 Completed 30 enrolled University Medical Center Hamburg-Eppendorf German Center for Infection Research · collab Ludwig-Maximilians - University of Munich · collab Philipps University Marburg · collab

Non-randomizedParallel-groupOpen-labelPrevention

Summary

In this phase I first-in-human clinical trial, healthy volunteers in two different dose cohorts will be vaccinated twice with the candidate vaccine MVA-SARS-2-S. A subgroup will receive a heterologous booster vaccination with a licensed COVID-19 vaccine. The aim of the study is to assess the safety and tolerability of the candidate vaccine and to characterize its immunogenicity.

Timeline

Start: 2020-10-05
Primary completion: 2021-08-24
Completion: 2021-08-24

Publications

Grewe I, Friedrich M, Dieck ML, Spohn M, Ly ML, Krahling V, Mayer L, Mellinghoff SC, Rottstegge M, Kraemer R, Volz A, Becker S, Fathi A, Dahlke C, Weskamm LM, Addo MM. MVA-based SARS-CoV-2 vaccine candidates encoding different spike protein conformations induce distinct early transcriptional responses which may impact subsequent adaptive immunity. Front Immunol. 2024 Dec 19;15:1500615. doi: 10.3389/fimmu.2024.1500615. eCollection 2024.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BNT162b2	Messenger RNA (mRNA)	—	—
Subject	MVA-SARS-2-S	Vaccine	1e+07 iu	—
Subject	MVA-SARS-2-S	Vaccine	1e+08 iu	—

Safety and Immunogenicity of the Candidate Vaccine MVA-SARS-2-S and a Booster Vaccination With a Licensed Vaccine Against COVID-19

Summary

Timeline

Publications

Drugs

Indications